Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
LIXTE Biotechnology reports 40% disease control rate in ovarian cancer trial combining LB-100 with dostarlimab, supporting expansion of patient enrollment. #Biotech #Oncology
2026-05-15T04:59:52.163Z